Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423999 | 0.99 | HRH3 (0.60) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL22348748 | 0.94 | LTA4H (0.62) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL2735456 | 0.92 | KDM4E (0.63) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL214059 | 0.90 | HRH3 (0.54) | HRH3KDM4EMEN1KMT2AHTT | |
| SCHEMBL1623288 | 0.87 | KDM4E (0.62) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL16442149 | 0.86 | HRH3 (0.52) | HRH3KDM4EMEN1KMT2AKCNH2 | |
| SCHEMBL214731 | 0.85 | KDM4E (0.51) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL14419427 | 0.85 | KDM4E (0.64) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL216071 | 0.84 | KDM4E (0.54) | HRH3KDM4ELTA4HPTGS2PTGS1 | |
| SCHEMBL13320395 | 0.84 | KDM4E (0.51) | HRH3KDM4ELTA4HPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-1699421-B1 | Lactate salts of quinolinone compounds and their pharmaceutical use | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040006101-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20040002518-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | HRH3 552/4885KDM4E 4366/4885LTA4H 2872/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | HRH3 1327/4885KDM4E 1830/4885LTA4H 3987/4885 |
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HRH3 1777/4885KDM4E 4627/4885LTA4H 2145/4885 |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HRH3 1162/4885KDM4E 3069/4885LTA4H 4378/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HRH3 1777/4885KDM4E 4627/4885LTA4H 2145/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HRH3 1777/4885KDM4E 4627/4885LTA4H 2145/4885 |
| US-20040002518-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | HRH3 552/4885KDM4E 4366/4885LTA4H 2872/4885 |
| US-20040006101-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HRH3 1777/4885KDM4E 4627/4885LTA4H 2145/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | HRH3 1052/4885KDM4E 3618/4885LTA4H 2832/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HRH3 1162/4885KDM4E 3069/4885LTA4H 4378/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HRH3 1162/4885KDM4E 3069/4885LTA4H 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.